Jaz­z's KRAS deal with Redx; Al­to Neu­ro­science up­sizes IPO

Plus, news about Pep­Gen and Jasper Ther­a­peu­tics:

Jazz Phar­ma­ceu­ti­cals buys Redx Phar­ma’s KRAS in­hibitors: The com­pa­ny is pay­ing Redx $10 mil­lion up­front, with mile­stones up to $870 mil­lion. The deal will ex­tend Redx’s run­way in­to 2025.

Al­to Neu­ro­science’s up­sized IPO: The Los Al­tos-based CNS biotech raised $147.9 mil­lion in its ini­tial pub­lic of­fer­ing, sell­ing 9.2 mil­lion shares at $16.00 each.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA